These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 27037661)

  • 41. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.
    Yamauchi PS; Bissonnette R; Teixeira HD; Valdecantos WC
    J Am Acad Dermatol; 2016 Sep; 75(3):612-618.e6. PubMed ID: 27061047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.
    Mendrinou E; Patsatsi A; Zafiriou E; Papadopoulou D; Aggelou L; Sarri C; Mamuris Z; Kyriakou A; Sotiriadis D; Roussaki-Schulze A; Sarafidou T; Vasilopoulos Y
    Pharmacogenomics J; 2017 Jun; 17(3):237-241. PubMed ID: 27044681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre.
    Vergou T; Moustou AE; Antoniou C
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e40-e41. PubMed ID: 27038363
    [No Abstract]   [Full Text] [Related]  

  • 44. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa.
    Navrazhina K; Frew JW; Gilleaudeau P; Sullivan-Whalen M; Garcet S; Krueger JG
    J Allergy Clin Immunol; 2021 Jun; 147(6):2213-2224. PubMed ID: 33548397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
    Timmermann S; Hall A
    Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
    Megna M; Camela E; Ruggiero A; Battista T; Martora F; Cacciapuoti S; Potestio L
    Clin Cosmet Investig Dermatol; 2023; 16():1677-1690. PubMed ID: 37404368
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Course and Characteristics of Generalized Pustular Psoriasis.
    Choon SE; Navarini AA; Pinter A
    Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):21-29. PubMed ID: 35061227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful Treatment of Recurrent Pustular Psoriasis of Pregnancy with Secukinumab: A Case Report.
    Liu N; Zhu L; Cheng Y; Yu N; Yi X; Ding Y
    Acta Derm Venereol; 2020 Aug; 100(15):adv00251. PubMed ID: 32812054
    [No Abstract]   [Full Text] [Related]  

  • 49. The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis.
    Sun L; Liu W; Zhang LJ
    J Immunol Res; 2019; 2019():1824624. PubMed ID: 31815151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis.
    Zhang LJ
    Front Immunol; 2019; 10():1440. PubMed ID: 31293591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Severe myalgia associated with brodalumab treatment in a patient with psoriasis.
    Ichiyama S; Matano Y; Hoashi T; Kanda N; Nagayama H; Saeki H
    J Dermatol; 2018 Dec; 45(12):e327-e328. PubMed ID: 29782052
    [No Abstract]   [Full Text] [Related]  

  • 52. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.
    Masson Regnault M; Konstantinou MP; Khemis A; Poulin Y; Bourcier M; Amelot F; Bulaï Livideanu C; Paul C
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1491-1496. PubMed ID: 28585707
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.
    Galluzzo M; Talamonti M; D'adamio S; Bianchi L
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):679-691. PubMed ID: 28460549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rebound pustular psoriasis after brodalumab discontinuation.
    Khemis A; Cavalié M; Montaudié H; Lacour JP; Passeron T
    Br J Dermatol; 2016 Nov; 175(5):1065-1066. PubMed ID: 27037661
    [No Abstract]   [Full Text] [Related]  

  • 55. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.
    Pinter A; Wilsmann-Theis D; Peitsch WK; Mössner R
    J Dermatol; 2019 May; 46(5):426-430. PubMed ID: 30786053
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brodalumab: A Review of Safety.
    Rusta-Sallehy S; Gooderham M; Papp K
    Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.